Minimally Invasive Healthcare (00853): Tianzhihang (688277.SH) plans to acquire a holding interest in Minimally Invasive Orthopedic Healthcare in Shanghai

Zhitong Finance App News, Minimally Invasive Healthcare (00853) announced that on July 15, 2026, the company's subsidiary Suzhou Minimally Invasive Orthopedics (Group) Co., Ltd. (Suzhou Minimally Invasive) signed a letter of intent with Beijing Tianzhihang Medical Technology Co., Ltd. (688277.SH), which states that Tianzhihang may acquire controlling interests in the target company from Suzhou Minimally Invasive and Shanghai Minimally Invasive Orthopedic Medical Technology Co., Ltd. (target companies, along with its subsidiaries, the “target group”). The price will be paid by Tianzhihang's issuance of new shares.

As of the date of the letter of intent, the target company was 82.29% of the shares held by Suzhou Weichuang and registered as a subsidiary of the company. It is the core operator of the Group's international (non-Chinese) orthopedic business. The target group is mainly engaged in hip and knee orthopedic reconstruction business in overseas markets such as the United States, Japan, and Europe. The target group has been deeply involved in the field of orthopedics for many years, focusing on R&D, production and sales of high-quality innovative hip and knee products that have been fully clinically proven, and has a mature and large-scale overseas sales network. Its representative product, internal axle knee prosthesis, has accumulated more than 20 years of clinical application history. According to relevant research results published in The Knee Journal, the 17-year cumulative retention rate of the target group's internal axle knee prosthesis was as high as 98.8%, and patient satisfaction reached 95%.

According to the announcement, the target group has a high-performance joint prosthesis product line and a mature marketing channel that has covered the overseas orthopedic market for many years, while Tianzhihang has deep accumulation and leading advantages in the field of orthopedic surgical robots. The business collaboration, strategy and long-term goals of the two parties are highly compatible. The potential deal is expected to unleash synergetic benefits far beyond separate operations by integrating the superior resources of both parties and reaching strong alliances, and help both parties achieve long-term performance growth.

Through potential transactions, the two sides are expected to continue to enhance the business scale, profitability and risk resilience of Tianzhi Airlines and the target group through business integration and the gradual release of synergy effects, thereby enhancing the long-term investment value of the group in the target group's business.